Wells Fargo’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Wells Fargo’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,406	Closed	-$2.69M	–	7764
2020 Q4	$2.69M	Sell	20,406 -3,306	-14%	-$292K	﹤0.01%	3277
2020 Q3	$1.2M	Buy	23,712 +1,865	+9%	+$83.8K	﹤0.01%	3714
2020 Q2	$1.04M	Buy	21,847 +4,091	+23%	+$190K	﹤0.01%	3785
2020 Q1	$871K	Buy	17,756 +5,196	+41%	+$265K	﹤0.01%	3633
2019 Q4	$721K	Buy	12,560 +6,178	+97%	+$306K	﹤0.01%	4090
2019 Q3	$230K	Buy	6,382 +59	+0.9%	+$2.31K	﹤0.01%	4876
2019 Q2	$196K	Sell	6,323 -3,300	-34%	-$89.5K	﹤0.01%	4991
2019 Q1	$225K	Buy	9,623 +5,319	+124%	+$85.4K	﹤0.01%	4762
2018 Q4	$59K	Buy	4,304 +3,278	+319%	+$41.4K	﹤0.01%	5471
2018 Q3	$10K	Buy	+1,026	New	+$16.9K	﹤0.01%	6002

Wells Fargo's EIDX Position: Q1 2021 in Review

Wells Fargo sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 20,406 shares — an estimated $2.69M sold.

Wells Fargo first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $2.69M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Wells Fargo reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Wells Fargo sold 20,406 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.69M.
Wells Fargo first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
Wells Fargo's Eidos Therapeutics, Inc. Common Stock position peaked at $2.69M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Wells Fargo's 13F filing for Q1 2021, filed 13 May 2021.